Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 17 Oct 2025

Integrating single-cell transcriptomics and whole-genome CRISPR CAS9 screen identifies a cell cluster associated with tumor dependency in triple-negative breast cancer

in Cancer Molecular Targets and Therapeutics

Su Liu
Shuo Wang
Guixin Wang
Yingxi Li
Zhigang Zhao
Yao Tian
Junming Cao

Frontiers in Oncology

doi 10.3389/fonc.2025.1705923

192 views

Review

Published on 16 Oct 2025

PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges

in Cancer Molecular Targets and Therapeutics

Sahar Ghoflchi
Ali Nakhaei
Farzaneh Abbasinezhad-Moud
Mohammad Jalili-Nik
Patrick J. Cimino

Frontiers in Oncology

doi 10.3389/fonc.2025.1669157

646 views

Case Report

Published on 16 Oct 2025

Case Report: Malignant peritoneal mesothelioma with TFG-ROS1 fusion responds to crizotinib

in Cancer Molecular Targets and Therapeutics

Wei Ye
Peng Li
Cong Fu
Tong Zhou

Frontiers in Oncology

doi 10.3389/fonc.2025.1617457

255 views

Brief Research Report

Published on 16 Oct 2025

Immunohistochemical analysis of Enolase-1 sublocalization in benign and malignant breast tumors: potential implications for tumor progression and prognosis

in Cancer Molecular Targets and Therapeutics

Laura de Souza Baracioli
Caroline Patini Rezende
Luadna dos Santos e Silva
Débora de Lima Alves
Daniela Farias da Nóbrega
Luiz Gustavo de Almeida Chuffa
Debora Aparecida Pires Campos Zuccari

Frontiers in Oncology

doi 10.3389/fonc.2025.1636394

319 views

Case Report

Published on 15 Oct 2025

Case Report: Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring NF1 mutation: a case series and literature review

in Cancer Molecular Targets and Therapeutics

Floryane Kim
Maxime Borgeaud
Claudio De Vito
Petros Tsantoulis
Alfredo Addeo

Frontiers in Oncology

doi 10.3389/fonc.2025.1481284

1,157 views

Original Research

Published on 14 Oct 2025

Integrated machine learning-based establishment of a prognostic model in multicenter cohorts for acute myeloid leukemia

in Cancer Molecular Targets and Therapeutics

Lin Yan
Huasong Yu
Xiaoyi Xu
Mingcheng Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1649594

781 views

Original Research

Accepted on 10 Oct 2025

ENGINEERED MULTIFUNCTIONAL TRANSFORMING GROWTH FACTOR (TGF)-b TYPE II RECEPTOR ECTODOMAIN FUSIONS FOR ONCOLOGY APPLICATIONS

in Cancer Molecular Targets and Therapeutics

Anne Engelina Gesina Lenferink
John Christian Zwaagstra
Jason Baardsnes
Laurence Delafosse
Marie Parat
Umar Iqbal
Etienne Lessard
Arsalan S Haqqani
Anna Jezierski
Afnan Abu-Thuraia

Frontiers in Oncology

doi 10.3389/fonc.2025.1648779

138 views

Editorial

Published on 10 Oct 2025

Editorial: Renewed insight into cancer mechanism and therapy

in Cancer Molecular Targets and Therapeutics

Yihao Liu
Lu Pan
Li Huang
Qinqin He
Hongbing Zhang
Jiadi Gan

Frontiers in Oncology

doi 10.3389/fonc.2025.1710803

429 views

Original Research

Published on 09 Oct 2025

CLIC6’s role in cancer: from broad analysis to breast cancer validation

in Cancer Molecular Targets and Therapeutics

Junyi Wang
Yiyang Wang
Haotian Ma
Yongxiang Li
Jiayue Hou
Jiaqi Li
Dilimulati Ismtula
Chenming Guo

Frontiers in Oncology

doi 10.3389/fonc.2025.1667589

551 views

Case Report

Accepted on 07 Oct 2025

HER2 Inhibitor-Based Combination Therapy for Recurrent and Metastatic Salivary Duct Carcinoma in an Elderly Patient: A Case Report and Literature Review

in Cancer Molecular Targets and Therapeutics

ZHANG Luxin
XU Xiaofeng
GAO Liujie
DING Jiyuan

Frontiers in Oncology

doi 10.3389/fonc.2025.1590497

123 views

Review

Accepted on 07 Oct 2025

Intratumoral heterogeneity in small cell lung cancer and potential treatment strategies

in Cancer Molecular Targets and Therapeutics

Yunke Yang
Nana Liu
Jiaji Wu
Qingzhe Wu
Jiangnan Zhao
Yue Shi
Mo Shen
Zhiyong Xu
Yueli Shi
Jianghao Yu

Frontiers in Oncology

doi 10.3389/fonc.2025.1657441

193 views

Original Research

Accepted on 07 Oct 2025

Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers

in Cancer Molecular Targets and Therapeutics

Daphne J F Kluitmans
Janneke J T M Melis
Esmee Van Den Bossche
Jacob Ytsma
Jeroen A D M De Roos
Oscar P J Van Linden
Yvonne Grobben
Jeffrey Kooijman
Guido J R Zaman

Frontiers in Oncology

doi 10.3389/fonc.2025.1667291

164 views

Original Research

Published on 07 Oct 2025

Construction of a prognostic model for colorectal cancer liver metastasis based on single-cell transcriptomics and regulation of the MIF pathway

in Cancer Molecular Targets and Therapeutics

Jianqiang Cao
Zhaobin He
HuiJie Gao
Yongzhe Yu
Shengbiao Yang
Xiqiang Wang
Jun Niu
Cheng Peng

Frontiers in Oncology

doi 10.3389/fonc.2025.1588514

828 views

Original Research

Published on 07 Oct 2025

Downregulation of SALL1 and its association with poor prognosis and the immune cell landscape in clear cell renal cell carcinoma

in Cancer Molecular Targets and Therapeutics

Gen-Yi Qu
Shao-Hao Chen
Meng-Xin Liu
Yi-Jie Wang
Zhao-Hui Long
Ning Xu
Xue-Yi Xue

Frontiers in Oncology

doi 10.3389/fonc.2025.1624651

616 views

Review

Published on 03 Oct 2025

Potential immunogenic modulation of hypo-fractionated radiotherapy at optimal schedules and the subsequent vaccine-like effect of local irradiation - a systematic review

in Cancer Molecular Targets and Therapeutics

Jagtar Singh
Martin Ashdown
Siddhartha Baxi

Frontiers in Oncology

doi 10.3389/fonc.2025.1546875

626 views

Mini Review

Published on 03 Oct 2025

The role of apelin in cancer

in Cancer Molecular Targets and Therapeutics

Yuki Agarwala
Rohini Sharma

Frontiers in Oncology

doi 10.3389/fonc.2025.1683865

723 views